SCHEMBL235437

SCHEMBL235437

COCCc1nc2ncncc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 1/20 0.41
METAP2 P50579 1/20 0.39
METAP1 P53582 1/20 0.39
NOS2 P35228 6/20 0.36
NOS1 P29475 5/20 0.36
NOS3 P29474 4/20 0.36
ENPP1 P22413 1/20 0.36
CYP2C9 P11712 2/20 0.36
NPY5R Q15761 1/20 0.34
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7851163 0.79 PI4KA (0.49) METAP2METAP1NOS2NOS1NOS3
SCHEMBL3054572 0.79 METAP2 (0.34) METAP2METAP1ENPP1GRIN2B
SCHEMBL6485 0.79 METAP2 (0.42) METAP2METAP1NOS2NOS1NOS3
SCHEMBL4955472 0.79 METAP2 (0.42) METAP2METAP1NOS2NOS1NOS3
SCHEMBL30884953 0.79 METAP2 (0.42) METAP2METAP1NOS2NOS1NOS3
SCHEMBL29208955 0.79 METAP2 (0.42) METAP2METAP1NOS2NOS1NOS3
SCHEMBL9569994 0.79 METAP2 (0.42) METAP2METAP1NOS2NOS1NOS3
SCHEMBL1193887 0.78 METAP2 (0.44) METAP2METAP1ENPP1NPY5RLMNA
SCHEMBL3691689 0.78 PI4KA (0.55) METAP2METAP1NOS2NOS1NOS3
SCHEMBL7073073 0.76 RAD52 (0.42) METAP2METAP1ENPP1NPY5RALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5849905-A Biologically active phosphotriester-type nucleosides and methods for preparing same CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1998-12-15 US claimed
US-5770725-A USES NOVEL GROUP, CHARACTERIZED BY THE PRESENCE OF-S-S-AND/OR S-C=Z (Z=O OR S) ENZYME LABILE BONDS WHICH LEADS, AFTER ENZYMATIC ACTIVATION, TO THE FORMATION OF UNSTABLE INTERMEDIATE WHICH RELEASES MONOPHOSPHATE OR MONOPHOSPHONATE CENTER NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1998-06-23 US claimed
EP-0642528-B1 PHOSPHOTRIESTER-TYPE BIOLOGICALLY ACTIVE COMPOUNDS CENTRE NAT RECH SCIENT (FR) 1997-01-15 EP claimed
EP-0642528-A1 PHOSPHOTRIESTER-TYPE BIOLOGICALLY ACTIVE COMPOUNDS. CENTRE NAT RECH SCIENT (FR) 1995-03-15 EP claimed
WO-1993024510-A1 PHOSPHOTRIESTER-TYPE BIOLOGICALLY ACTIVE COMPOUNDS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1993-12-09 WO claimed
US-20220056441-A1 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) SIRNA THERAPEUTICS INC (US) 2022-02-24 US disclosed
EP-3926046-A2 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) Sirna Therapeutics, Inc. (US) 2021-12-22 EP disclosed
EP-3354656-B1 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) SIRNA THERAPEUTICS INC (US) 2021-04-07 EP disclosed
US-10889815-B2 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) SIRNA THERAPEUTICS, INC. (US) 2021-01-12 US disclosed
US-10662428-B2 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) SIRNA THERAPEUTICS, INC. (US) 2020-05-26 US disclosed
US-20190233821-A1 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) BANK OF AMERICA, N.A. 2019-08-01 US disclosed
US-10351852-B2 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) SIRNA THERAPEUTICS, INC. (US) 2019-07-16 US disclosed
US-20020037873-A1 Biologically active phosphotriester-type compounds CENTRE NATIONAL DE LA RECHERCH SIENTIFIQUE 2002-03-28 US disclosed
US-6020482-A Phosphotriester type biologically active compounds CENTER NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2000-02-01 US disclosed
US-5849905-A Biologically active phosphotriester-type nucleosides and methods for preparing same CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1998-12-15 US disclosed
US-5770725-A USES NOVEL GROUP, CHARACTERIZED BY THE PRESENCE OF-S-S-AND/OR S-C=Z (Z=O OR S) ENZYME LABILE BONDS WHICH LEADS, AFTER ENZYMATIC ACTIVATION, TO THE FORMATION OF UNSTABLE INTERMEDIATE WHICH RELEASES MONOPHOSPHATE OR MONOPHOSPHONATE CENTER NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1998-06-23 US disclosed
WO-1998011121-A1 BIOLOGICALLY ACTIVE PHOSPHOTRIESTER-TYPE COMPOUNDS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1998-03-19 WO disclosed
EP-0642528-B1 PHOSPHOTRIESTER-TYPE BIOLOGICALLY ACTIVE COMPOUNDS CENTRE NAT RECH SCIENT (FR) 1997-01-15 EP disclosed
EP-0642528-A1 PHOSPHOTRIESTER-TYPE BIOLOGICALLY ACTIVE COMPOUNDS. CENTRE NAT RECH SCIENT (FR) 1995-03-15 EP disclosed
WO-1993024510-A1 PHOSPHOTRIESTER-TYPE BIOLOGICALLY ACTIVE COMPOUNDS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1993-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10662428-B2 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) AGO2, SNRPE, SRRT CACNA1H 3019/4885METAP2 2389/4885METAP1 1994/4885
US-10889815-B2 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) AGO2, SNRPE, SRRT CACNA1H 3019/4885METAP2 2389/4885METAP1 1994/4885
US-20220056441-A1 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) AGO2, SNRPE, SRRT CACNA1H 3019/4885METAP2 2389/4885METAP1 1994/4885
US-20190233821-A1 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) AGO2, SNRPE, SRRT CACNA1H 3019/4885METAP2 2389/4885METAP1 1994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.